Drug Trial Radar · NCT06672536
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Nov 26, 2024
Primary completion
Sep 23, 2026
Study completion Jan 11, 2027
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Tianjin Medical University Eye Hospital
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Conditions
- nAMD
Interventions
SCT520FFDrug
SCT520FF dose level 1,IVI
SCT520FFDrug
SCT520FF dose level 2,IVI
SCT520FFDrug
SCT520FF dose level 3,IVI
EYLEA 2 MGDrug
EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events(TEAE)Time frame: From Day 0 up to 196days
- Treatment-related treatment emergent adverse events(TRAE)Time frame: From Day 0 up to 196days
- Serious adverse event(SAE)Time frame: From Day 0 up to 196days
- Adverse event of special interest(AESI)Time frame: From Day 0 up to 196days
- Dose limited toxicity(DLT)Time frame: From Day 0 up to 196days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Eye Hospital
Tianjing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.